Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...

Stocks turned in a lackluster performance Friday as Wall Street took a breather at the end of the first week of ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Sarepta Therapeutics, Inc. ( NASDAQ: SRPT) Strategic Restructure and ELEVIDYS Label Update Conference Call July 16, 2025 4:30 PM ET Douglas S. Ingram - President, CEO & Director Ian Estepan - ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) continued to fall on Friday as Reuters reported that the U.S. FDA plans to ...

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene ...

Stocks on Sky High. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the top-performing companies on Thursday. Sarepta ...

Shares of Sarepta Therapeutics declined 17% in early trading on Friday after another patient who had received an experimental ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. (“Sarepta” ...